Dermatology and Inflammatory Skin Disease
Clinical research is concentrated in ulcerative pyoderma gangrenosum, with additional activity in hidradenitis suppurativa and chronic spontaneous urticaria. These programmes reflect a focus on difficult-to-treat inflammatory dermatologic disorders with significant symptom burden.
- Ulcerative pyoderma gangrenosum
- Hidradenitis suppurativa
- Chronic spontaneous urticaria
Study activity includes patients with moderate to severe disease as well as healthy volunteers for comparative safety and pharmacology assessments.
Immunology and Complement-Mediated Inflammation
The sponsor’s portfolio includes investigation of vilobelimab in pyoderma gangrenosum, indicating interest in immune-driven inflammatory pathways relevant to refractory skin disease.
- Immune-mediated inflammation
- Complement pathway targeting
- Neutrophilic dermatoses
This area links systemic inflammatory biology with cutaneous disease expression.
Small-Molecule Therapeutics and Pharmacokinetics
Research involving INF904 centers on safety, pharmacokinetics, bioavailability, food effects, and metabolite profiling, with evaluation in both patient populations and healthy participants.
- Oral formulation development
- Bioavailability assessment
- Metabolite profiling
The programme spans early clinical characterization alongside disease-focused evaluation in CSU and HS.
Clinical Pharmacology and Healthy Volunteer Studies
Trials in healthy male participants support foundational clinical pharmacology work for izicopan and related compounds, complementing patient studies in inflammatory conditions.
- Single-dose pharmacology
- Mass balance evaluation
- Metabolic characterization
These studies contribute to understanding exposure, disposition, and safety across early human research settings.
